AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02509143
Drug: Intravenous infusion of ramosetron
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Ramosetron (DB09290)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion of (oxycodone 20mg, ketorolac 120mg, ramosetron 0.3mg) as standard antiemetic medication will be provided. A dose of continuous infusion will be reduced by 0.1 ml/hr when a patient complaints of nausea.~When vomiting occurs, a dose of continuous infusion will be reduced by 0.2 ml/hr and a bolus infusion of ramosetron 0.3 mg will be provided. A bolus infusion of ramosetron 0.3 mg will be also given if a patient feels greater than or equal to six points of nausea as measured on a 0 to 10 numeric rating scale (NRS) (nausea-severity scale) or by the patient's request, regardless of the severity of the nausea.
Trial: NCT01860638
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).
Trial: NCT01860638
Drug: Lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m\^2 PO Q6W, with a cap of 200 mg per dose.
Trial: NCT03899454
Drug: Garcinia-mangostana-L-rind and Solanum-Lycopersicum-Fructus mixture-extract
RxNorm normalized name: Garcinia mangostana fruit rind extract
DrugBank: Mango (DB10657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
Trial: NCT01860638
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide will be administered orally (PO) as 75 mg/m\^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m\^2 per day for the first 5 days of Cycle 1, then 200 mg/m\^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.
Trial: NCT01756885
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
Trial: NCT01221571
Drug: AFM 13
RxNorm normalized name: AFM-13
DrugBank: Acimtamig (DB18674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.
Trial: NCT00273000
Drug: GLP-2
RxNorm normalized name: (Gly2)GLP-2
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00897676
Drug: Exendin-(9-39)
RxNorm normalized name: Exendin 4
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-500pmol/kg/min
Trial: NCT01987505
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1400 mg will be injected subcutaneously (SC).
Trial: NCT01833520
Drug: Ra-223 Dichloride
RxNorm normalized name: RADIUM RA-223 DICHLORIDE
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I.
Trial: NCT01328925
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide Oral Suspension dose based on age:~Age \<12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days
Trial: NCT04502589
Drug: Perampanel Tablet
RxNorm normalized name: Perampanel Tablets
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will be titrated over 3 weeks to a target dose of 8mg perampanel daily in both groups
Trial: NCT00051155
Drug: Travoprost (0.004%)
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00051155
Drug: Latanoprost (0.005%)/Timolol (0.5%)
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00023764
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01009476
Drug: Galantamine
RxNorm normalized name: Galantamine
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) was to be in accordance with the recommendations given in the summary of product characteristics.
Trial: NCT02407704
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02407704
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
Trial: NCT00690495
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol (drug), intravenous, induction of anesthesia
Trial: NCT00690495
Drug: Propofol 1%
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol (drug), intravenous, induction of anesthesia
Trial: NCT02504450
Drug: Adasuve
RxNorm normalized name: Adasuve
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled medication to treat acute agitation in the emergency department
Trial: NCT02504450
Drug: Alternative medications
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication given to treat acute agitation in the emergency department
Trial: NCT01685255
Drug: Epacadostat
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01685255
Drug: tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00577655
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.
Trial: NCT01632423
Drug: bimatoprost 0.01%
RxNorm normalized name: BIMATOPROST 0.01% OPH SOLN
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
Trial: NCT03926169
Drug: Risankizumab
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
Trial: NCT03926169
Drug: Placebo for risankizumab
RxNorm normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo for risankizumab is administered as a SC injection in PFS
Trial: NCT00837564
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
Trial: NCT03473132
Drug: four factor prothrombin complex concentrate
RxNorm normalized name: Prothrombin complex concentrate
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After treatment with 4F-PCC, coagulation factor levels will be assessed. Time to return to anticoagulation target INR will also be determined.
Trial: NCT03598595
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03598595
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03598595
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00945490
Drug: NX-1207
RxNorm normalized name: NX-1207
DrugBank: NX-1207 (DB05493)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraprostatic injection of 2.5 mg NX-1207
Trial: NCT02757703
Drug: Somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
Trial: NCT02757703
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
Trial: NCT02757703
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
Trial: NCT03519646
Drug: Eliglustat
RxNorm normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1. This is a 3-year study and the enrollment time of this study is 24 months.~2. The participants have to receive the investigational agent, Cerdelga~3. The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.~4. IMP Administration Method: Cerdelga have 21 mg、42 mg and 84 mg capsule.~5. No need for fasting before use, but can't take with grapefruit juice.~6. Five ml Blood and 10 ml urine shoud be taken before receiving Cerdelga, and 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga for Gaucher related biomarkers test.
Trial: NCT01937117
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
Trial: NCT01937117
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 840 mg as a loading dose, then 420 mg every 3 weeks, IV
Trial: NCT03359876
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg, once daily
Trial: NCT03359876
Drug: Warfarin sodium
RxNorm normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually adjusted dose
Trial: NCT00428597
Drug: sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * sunitinib malate oral starting dose 37.5 mg daily (continuous dosing).~* Dose may be decreased to 25 mg daily in case of adverse events.~* It may be increased to 50 mg daily if no response is seen after 8 weeks on treatment.~* Dosing to continue until unacceptable toxicity, progression of disease, death, or study termination.
Trial: NCT01316237
Drug: GS-6620
RxNorm normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-6620 tablet, 50 mg QD
Trial: NCT01316237
Drug: GS-6620
RxNorm normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-6620 tablet, 100 mg QD
Trial: NCT01316237
Drug: GS-6620
RxNorm normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-6620 tablet, 300 mg QD
Trial: NCT01316237
Drug: GS-6620
RxNorm normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-6620 tablet, 100 mg QD, Fasted
Trial: NCT01316237
Drug: GS-6620
RxNorm normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-6620 tablet, 300 mg QD, Fasted
Trial: NCT01316237
Drug: GS-6620
RxNorm normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-6620 tablet, 900 mg QD, Fasted
Trial: NCT01316237
Drug: GS-6620 tablet, 450 mg BID
DrugBank: GS-6620 (DB15222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-6620 tablet, 450 mg BID
Trial: NCT01316237
Drug: GS-6620 tablet
RxNorm normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-6620 tablet, 900mg , BID
Trial: NCT01316237
Drug: GS-6620 tablet
RxNorm normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-6620 tablet, 900 mg
Trial: NCT03306758
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Bicarbonate was given 1g tid for one month
Trial: NCT01284166
Drug: dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 drop of Triple Combination Therapy (dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution) administered to each eye, twice daily for 12 weeks.
Trial: NCT00685334
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take olanzapine daily for 12 weeks.
Trial: NCT00685334
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will take aripiprazole daily for 12 weeks.
Trial: NCT00803816
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: everolimus 1.0 - 2.5mg oral daily dosage
Trial: NCT02654730
Drug: Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient
RxNorm normalized name: methyl-dihydroartemisinine
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days
Trial: NCT03607331
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
Trial: NCT00330473
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient specific dose, oral or injectable, before meals and/or as needed, 9 months. ( patients and investigator determine standard option therapy)
Trial: NCT05156541
Drug: Interferon gamma human recombinant (IFN-G)
RxNorm normalized name: interferon gamma, porcine recombinant
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Trial: NCT04342936
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A humanized monoclonal immunoglobulin
Trial: NCT01441349
Drug: IP chemotherapy
RxNorm normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan/cisplatin (IP) chemotherapy~* Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8.~* Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1 \& 8~* Every 21 days
Trial: NCT00452218
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg daily and dose escalated to a maximum of 400 mg twice daily
Trial: NCT01717313
Drug: Omarigliptin
RxNorm normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Omarigliptin 25 mg capsule administered orally once a week.
Trial: NCT01717313
Drug: Placebo to Omarigliptin
DrugBank: Omarigliptin (DB11992)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Placebo to omarigliptin capsule administered orally once a week
Trial: NCT01717313
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
Trial: NCT01717313
Drug: Placebo to metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: During Phase B of the study, participants in the omarigliptin treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).
Trial: NCT01717313
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
Trial: NCT00209690
Drug: Taxotere
RxNorm normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT00209690
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg/m2, CIV (conti.in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT00209690
Drug: Briplatin
RxNorm normalized name: Aroplatin
DrugBank: Aroplatin (DB17319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT03633721
Drug: Cannabis
RxNorm normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
Trial: NCT00375284
Drug: Pramipexole
RxNorm normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02654730
Drug: Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
Trial: NCT02864472
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab
Trial: NCT02864472
Drug: ranibizumab PRN
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ranibizumab PRN
Trial: NCT04033419
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: memantine dose~* Week 1: 5 mg dose once daily~* Week 2: 5 mg dose twice daily~* Week 3: 5 mg each morning/10 mg each evening~* Week 4 through the end of Chemotherapy: 10 mg dose twice daily~* Total duration: 12 - 26 weeks (depending on chemotherapy regimen)
Trial: NCT00276536
Drug: IFN
RxNorm normalized name: IFNτ
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN daily
Trial: NCT02662647
Drug: Decitabine 20 mg/m²/day for 5 days
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01002079
Drug: BMS-708163
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule, Oral, 125 mg, Once daily, 1 day
Trial: NCT01002079
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, 600 mg, Once daily, 7 days